Equity · Healthcare
ADPT
NASDAQAdaptive Biotechnologies (ADPT)
The line runs 25 USD on 12 August through 30.25 USD on 9 November, on a scale from 22.5 to 32.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 4.9B USD
- Revenue, year to Dec 2025
- 277.0M USD
- EPS, diluted, year to Dec 2025
- −0.39 USD
- 52-week range
- 12.42 USD – 30.25 USD
- Avg volume
- 147.3K
as of Nov 9, 2026
Have Adaptive Biotechnologies (ADPT) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Adaptive Biotechnologies insiders reported 36 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Jul 2026, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 6 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 327K USD |
| 05 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 315K USD |
| 04 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 313K USD |
| 03 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 309K USD |
| 02 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 303K USD |
| 30 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 318K USD |
| 29 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 336K USD |
| 28 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 338K USD |
| 27 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 324K USD |
| 26 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 309K USD |
| 23 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 297K USD |
| 22 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Sell | 11,881 | 291K USD |
| Sold | 36 open-market sales | 1,235,593 | $31.68M |
Showing the 12 most recent of 36 open-market trades in this window. The figures above count all of them.
34 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 05 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 04 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 03 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 02 Nov 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 30 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 29 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 28 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 27 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 26 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 23 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
| 22 Oct 2026 | RUBINSTEIN JULIEPresident and COO | Option exercise | 11,881 | 144K USD |
Showing the 12 most recent of 34 compensation filings in this window. The figures above count all of them.
Which funds hold Adaptive Biotechnologies (ADPT)?
11 of the 45 institutional funds we track reported a Adaptive Biotechnologies position for the quarter ended 30 Jun 2026 — a combined 837.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Viking Global Investors | Held (±25%) | 29,993,708 | 643.4M USD | |
| D. E. Shaw & Co. | Added | 4,625,859 | 99.2M USD | +135.3% |
| ARK Investment Management | Held (±25%) | 2,090,306 | 44.8M USD | −0.1% |
| Tudor Investment Corp | Trimmed | 543,485 | 11.7M USD | −30.9% |
| Millennium Management | Trimmed | 504,909 | 10.8M USD | −53.3% |
| AQR Capital Management | Trimmed | 362,916 | 7.8M USD | −25.2% |
| Renaissance Technologies | Added | 302,800 | 6.5M USD | +26.3% |
| Marshall Wace | Added | 292,079 | 6.3M USD | +238.3% |
| Citadel Advisors | Trimmed | 181,356 | 3.9M USD | −50.1% |
| Man Group | Trimmed | 91,921 | 2.0M USD | −62.6% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
What has been filed or recorded for Adaptive Biotechnologies (ADPT)?
The filings we hold for Adaptive Biotechnologies, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,359 shares | 88K USD notional · 0.002% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,287 shares | 35K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.02 USD | Revenue $84M |
| 30 Sep 2026 | Financials | Total assets | 683.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 176.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.25 USD | Revenue $72M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.13 USD | Revenue $71M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.39 USD | Revenue $277M |
| 31 Dec 2025 | Financials | Revenue | 277.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −59.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.39 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.06 USD | Revenue $94M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.17 USD | Revenue $59M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.20 USD | Revenue $52M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.08 USD | Revenue $179M |
What do people ask about Adaptive Biotechnologies (ADPT)?
What did Adaptive Biotechnologies shares close at?30.25
Adaptive Biotechnologies closed at 30.25 USD on 9 Nov 2026, up 8.15% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Adaptive Biotechnologies’ market cap?4.9B
Adaptive Biotechnologies is worth 4.9B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Adaptive Biotechnologies’ revenue?277.0M
Adaptive Biotechnologies reported revenue of 277.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Adaptive Biotechnologies insiders bought or sold shares recently?36 sales
In the 90 days to 10 Nov 2026, Adaptive Biotechnologies insiders reported 36 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Jul 2026, show no open-market purchase. A further 34 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Adaptive Biotechnologies?11 of 45
11 of the 45 funds we track reported a Adaptive Biotechnologies position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, D. E. Shaw & Co. and ARK Investment Management. See Funds
When did Adaptive Biotechnologies last report earnings?0.02
Adaptive Biotechnologies last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.02 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings